Department of Neurology, St, Antonius, Utrecht, the Netherlands.
Department of Neurology, St, Antonius, Utrecht, the Netherlands.
Mult Scler Relat Disord. 2020 May;40:101978. doi: 10.1016/j.msard.2020.101978. Epub 2020 Jan 31.
A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.
一位 38 岁男性，患有复发缓解型多发性硬化症（RRMS），在过去五年中接受 fingolimod 治疗，病情稳定，无临床和影像学进展，后出现肿块样脱髓鞘病变（TDL）。MS 中的 TDL 倾向于在疾病早期发生，在长期 MS 中并不常见。与用于 MS 的其他免疫调节药物相比，在使用 fingolimod 治疗下，描述 TDL 发展的报告相对较多且仍在增加，提示 fingolimod 与 TDL 之间存在因果关系。
